This site is intended for healthcare professionals only
LoginRegister

Bristol Myers sues AstraZeneca over cancer-treatment patents

MD BureauWritten by MD Bureau   |  
Bristol Myers sues AstraZeneca over cancer-treatment patents

Bristol asked the Delaware court for an undisclosed amount of monetary damages.

New Delhi: Bristol Myers Squibb Co, in a lawsuit made public on Friday, said AstraZeneca's cancer treatment Imfinzi violates patents related to its blockbuster cancer drug Opdivo. The lawsuit https://tmsnrt.rs/3ieYLvz in Delaware federal court said that the use of Imfinzi to treat lung and bladder cancer infringes several patents on Bristol's immunotherapy Opdivo.An...

New Delhi: Bristol Myers Squibb Co, in a lawsuit made public on Friday, said AstraZeneca's cancer treatment Imfinzi violates patents related to its blockbuster cancer drug Opdivo. The lawsuit https://tmsnrt.rs/3ieYLvz in Delaware federal court said that the use of Imfinzi to treat lung and bladder cancer infringes several patents on Bristol's immunotherapy Opdivo.

An AstraZeneca spokesperson said on Friday that the company was reviewing the complaint and would respond "at the appropriate time." A representative for Bristol Myers declined to comment.
New York-based Bristol Myers recorded over $7.5 billion from worldwide sales of Opdivo last year. Imfinzi brought in over $2.4 billion in sales for the British drugmaker last year.
Bristol asked the Delaware court for an undisclosed amount of monetary damages.
Opdivo (nivolumab) is a monoclonal antibody designed to block a protein that cancer cells use to avoid the immune system. The treatment essentially takes the brakes off the immune system to fight the cancer. Opdivo is approved for use against many types of cancer including melanoma and advanced lung, bladder and kidney cancer.
Imfinzi (duralumab) works in a similar manner. The complaint, which cites several patents, says Bristol invented the methods for enhancing immune responses.
A Bristol Myers subsidiary previously won $1.2 billion from a Gilead Sciences unit whose lymphoma immunotherapy Yescarta from a different class of medicines was found to infringe one of its patents. A U.S. appeals court threw out that award last year.

Read Also - AstraZeneca's Young Health Program opens 3 Health Information Centres (HICs) in Bangalore



Bristol Myers AstraZeneca cancer-treatment patents Delaware court monetary damage Opdivo nivolumab 
Source : Reuters
MD Bureau
MD Bureau

    Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    Include Cy-Tb injection in national TB elimination programme: SII urges MoHFW

    Include Cy-Tb injection in national TB elimination programme: SII urges MoHFW

    Cipla Indore plant gets 2 USFDA observations

    Cipla Indore plant gets 2 USFDA observations

    Dr Reddys Labs unit inks drug discovery, development pact with EQRx

    Dr Reddy's Labs unit inks drug discovery, development pact with EQRx

    Antianginal drug Trimetazidine links with DRESS Syndrome: IPC drug safety alert

    Antianginal drug Trimetazidine links with DRESS Syndrome: IPC drug safety alert

    Sanofi Global Health unveils new brand Impact for distribution of 30 medicines in low-income countries

    Sanofi Global Health unveils new brand Impact for distribution of 30 medicines in low-income...

    Apple Watch Series 8 to come up with fever detection feature

    Apple Watch Series 8 to come up with fever detection feature

    Mississippi cant ban pill despite US Supreme Court ruling: Abortion drug maker GenBioPro

    Mississippi can't ban pill despite US Supreme Court ruling: Abortion drug maker GenBioPro

    German health minister in move to boost COVID drug Paxlovid use

    German health minister in move to boost COVID drug Paxlovid use

    Union Health Minister discusses roadmap for Indian pharma sector

    Union Health Minister discusses roadmap for Indian pharma sector

    Merck launches Merck Digital Sciences Studio for healthcare startups

    Merck launches Merck Digital Sciences Studio for healthcare startups

    Novartis leaning toward spinoff of USD 25 billion generics arm: Bloomberg

    Novartis leaning toward spinoff of USD 25 billion generics arm: Bloomberg

    Novavax likely to come up with COVID vaccine targeting Omicron in Q4

    Novavax likely to come up with COVID vaccine targeting Omicron in Q4

    Oxford Biomedica signs new deal to make AstraZeneca COVID vaccine

    Oxford Biomedica signs new deal to make AstraZeneca COVID vaccine

    X
    X